Eqis Capital Management Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,283 shares of the biopharmaceutical company’s stock after selling 8,572 shares during the period. Gilead Sciences comprises 0.4% of Eqis Capital Management Inc.’s investment portfolio, making the stock its 26th largest position. Eqis Capital Management Inc.’s holdings in Gilead Sciences were worth $7,153,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the business. Northwest Bancshares Inc. lifted its position in shares of Gilead Sciences by 8.9% during the third quarter. Northwest Bancshares Inc. now owns 28,816 shares of the biopharmaceutical company’s stock worth $2,224,000 after purchasing an additional 2,344 shares in the last quarter. DnB Asset Management AS lifted its position in shares of Gilead Sciences by 4.4% during the second quarter. DnB Asset Management AS now owns 156,552 shares of the biopharmaceutical company’s stock worth $11,090,000 after purchasing an additional 6,600 shares in the last quarter. Swedbank lifted its position in shares of Gilead Sciences by 103.7% during the third quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock worth $301,596,000 after purchasing an additional 1,988,987 shares in the last quarter. Fairpointe Capital LLC acquired a new position in shares of Gilead Sciences during the second quarter worth $708,000. Finally, Gamco Investors INC. ET AL lifted its position in shares of Gilead Sciences by 15.4% during the second quarter. Gamco Investors INC. ET AL now owns 14,980 shares of the biopharmaceutical company’s stock worth $1,061,000 after purchasing an additional 2,000 shares in the last quarter. 77.99% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:GILD opened at $75.62 on Thursday. The company has a debt-to-equity ratio of 1.23, a current ratio of 3.00 and a quick ratio of 2.92. The firm has a market capitalization of $100.09 billion, a P/E ratio of 8.83, a P/E/G ratio of -3.92 and a beta of 1.01. Gilead Sciences, Inc. has a 12-month low of $64.27 and a 12-month high of $89.54.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.56 by $0.35. The business had revenue of $5.65 billion during the quarter, compared to analyst estimates of $5.20 billion. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The business’s revenue was down 20.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.56 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post 6.56 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 27th. Investors of record on Friday, September 14th were paid a $0.57 dividend. The ex-dividend date of this dividend was Thursday, September 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.02%. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.
In related news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $74.16, for a total value of $3,708,000.00. Following the completion of the sale, the director now owns 3,067,762 shares in the company, valued at $227,505,229.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders sold 150,000 shares of company stock valued at $11,502,500. Insiders own 1.16% of the company’s stock.
A number of research analysts have recently commented on the stock. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, October 11th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Monday, October 1st. They set an “overweight” rating and a $87.00 target price on the stock. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday, September 28th. Zacks Investment Research cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 25th. Finally, Piper Jaffray Companies set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, September 12th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $88.24.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Recommended Story: What are the Different Types of Leveraged Buyouts?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.